Research

Mixed

In nonmetastatic colorectal cancer patients, the co-occurrence of systemic inflammation (elevated neutrophil-to-lymphocyte ratio ≥3) and sarcopenia (low skeletal muscle index) doubles the risk of overall and cancer-specific mortality compared to having neither condition.

If you have early-stage colorectal cancer, ask your care team to check your muscle mass (via CT scan) and inflammation markers (blood test) early on. Having both low muscle and high inflammation significantly increases your risk of death, but because these factors are modifiable, identifying them opens the door for interventions like resistance training and nutritional support to potentially improve your survival chances.

GoodSupportsHIGH confidence
Patients with both sarcopenia and NLR of 3 or greater (vs neither) had double the risk of death, overall (HR, 2.12; 95% CI, 1.70-2.65) and CRC related (HR, 2.43; 95% CI, 1.79-3.29).
Elizabeth M. Cespedes Feliciano et al. · JAMA Oncology · 2017

Why this rating

Large prospective cohort (n=2470), rigorous statistical adjustment for confounders, but observational design prevents causal inference.

Source

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer

Elizabeth M. Cespedes Feliciano et al. · JAMA Oncology · 2017

DOI 10.1001/jamaoncol.2017.2319

cohort · n=2470Cited 422×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →